Loading...
XHKG
6821
Market cap2.99bUSD
Apr 11, Last price  
43.65HKD
1D
-0.57%
1Q
-5.11%
IPO
-83.48%
Name

Asymchem Laboratories Tianjin Co Ltd

Chart & Performance

D1W1MN
P/E
6.05
P/S
1.76
EPS
6.78
Div Yield, %
4.53%
Shrs. gr., 5y
2.37%
Rev. gr., 5y
33.65%
Revenues
5.80b
-25.82%
405,691,300424,399,200542,757,593716,207,193830,607,6941,103,194,9521,423,033,4121,834,877,6242,459,985,5333,149,689,6754,638,834,17710,255,325,3927,825,190,2985,804,657,336
Net income
949m
-58.17%
65,372,50060,251,40074,729,476101,791,578153,545,023252,735,199341,287,654428,295,474553,863,836722,091,3601,069,273,5773,301,635,0192,268,810,444948,950,036
CFO
1.25b
-64.66%
25,883,50034,384,900105,917,363127,045,751256,994,132278,355,646196,400,310415,060,930600,867,843569,291,589113,150,1213,286,910,7053,549,728,3831,254,337,014
Dividend
Jun 13, 20241.9767 HKD/sh
Earnings
Jun 06, 2025

Profile

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
URL
https://www.asymchem.com.cn/
IPO date
Nov 18, 2016
Employees
9,719
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,804,657
-25.82%
7,825,190
-23.70%
10,255,325
121.08%
Cost of revenue
4,291,988
4,898,684
6,492,121
Unusual Expense (Income)
NOPBT
1,512,669
2,926,506
3,763,204
NOPBT Margin
26.06%
37.40%
36.70%
Operating Taxes
136,625
306,310
430,314
Tax Rate
9.03%
10.47%
11.43%
NOPAT
1,376,044
2,620,196
3,332,891
Net income
948,950
-58.17%
2,268,810
-31.28%
3,301,635
208.77%
Dividends
(641,939)
(663,897)
(211,272)
Dividend yield
2.39%
1.58%
0.39%
Proceeds from repurchase of equity
(9,317)
BB yield
0.02%
Debt
Debt current
12,228
28,487
Long-term debt
565,058
212,972
219,719
Deferred revenue
298,622
232,599
168,121
Other long-term liabilities
785
1
Net debt
(5,918,700)
(9,657,752)
(7,192,451)
Cash flow
Cash from operating activities
1,254,337
3,549,728
3,286,911
CAPEX
(1,241,610)
Cash from investing activities
(2,890,264)
Cash from financing activities
(542,029)
FCF
(43,392)
2,865,501
1,443,746
Balance
Cash
7,329,218
9,015,765
7,440,656
Long term investments
(845,460)
867,186
Excess cash
6,193,525
9,491,692
6,927,890
Stockholders' equity
8,462,911
8,159,656
6,572,500
Invested Capital
11,250,985
9,701,636
9,311,618
ROIC
13.13%
27.56%
41.55%
ROCE
8.60%
16.28%
23.56%
EV
Common stock shares outstanding
352,770
362,430
366,848
Price
76.09
-34.47%
116.12
-21.54%
148.00
-65.98%
Market cap
26,842,234
-36.22%
42,085,346
-22.49%
54,293,554
-63.43%
EV
20,940,722
32,457,857
48,097,562
EBITDA
2,015,182
3,390,449
4,104,941
EV/EBITDA
10.39
9.57
11.72
Interest
9,505
6,322
10,529
Interest/NOPBT
0.63%
0.22%
0.28%